LifeMD, Inc. (LFMD)
NASDAQ: LFMD · Real-Time Price · USD
3.230
-0.010 (-0.31%)
At close: Dec 19, 2025, 4:00 PM EST
3.270
+0.040 (1.24%)
After-hours: Dec 19, 2025, 7:58 PM EST
LifeMD Revenue
LifeMD had revenue of $60.17M in the quarter ending September 30, 2025, with 12.95% growth. This brings the company's revenue in the last twelve months to $251.21M, up 30.20% year-over-year. In the year 2024, LifeMD had annual revenue of $212.45M with 39.27% growth.
Revenue (ttm)
$251.21M
Revenue Growth
+30.20%
P/S Ratio
0.57
Revenue / Employee
$814,631
Employees
307
Market Cap
155.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 212.45M | 59.91M | 39.27% |
| Dec 31, 2023 | 152.55M | 33.51M | 28.15% |
| Dec 31, 2022 | 119.03M | 26.16M | 28.16% |
| Dec 31, 2021 | 92.88M | 55.58M | 149.04% |
| Dec 31, 2020 | 37.29M | 24.83M | 199.10% |
| Dec 31, 2019 | 12.47M | 4.14M | 49.79% |
| Dec 31, 2018 | 8.32M | 4.64M | 126.09% |
| Dec 31, 2017 | 3.68M | -1.56M | -29.72% |
| Dec 31, 2016 | 5.24M | 4.02M | 329.79% |
| Dec 31, 2015 | 1.22M | 504.70K | 70.67% |
| Dec 31, 2014 | 714.16K | -94.21K | -11.65% |
| Dec 31, 2013 | 808.36K | 134.59K | 19.97% |
| Dec 31, 2012 | 673.78K | -70.05K | -9.42% |
| Dec 31, 2011 | 743.83K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LFMD News
- 26 days ago - LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026 - GlobeNewsWire
- 4 weeks ago - LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - LifeMD Stock Plummets After Q3 Earnings: Here's Why - Benzinga
- 4 weeks ago - LifeMD Reports Third Quarter 2025 Results - GlobeNewsWire
- 4 weeks ago - LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk - GlobeNewsWire
- 5 weeks ago - LifeMD to Participate in the BTIG Digital Health Forum - GlobeNewsWire
- 6 weeks ago - LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17 - GlobeNewsWire
- 6 weeks ago - LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform - GlobeNewsWire